Neurocrine Biosciences (NBIX) Given a $85.00 Price Target at Oppenheimer

Oppenheimer set a $85.00 price target on Neurocrine Biosciences (NASDAQ:NBIX) in a report issued on Tuesday. The firm currently has a buy rating on the stock.

NBIX has been the topic of a number of other research reports. Piper Jaffray Companies set a $68.00 price target on Neurocrine Biosciences and gave the stock a buy rating in a research report on Thursday, August 24th. Citigroup reiterated a buy rating and set a $79.00 price target on shares of Neurocrine Biosciences in a research report on Thursday, November 2nd. Needham & Company LLC reiterated a buy rating and set a $86.00 price target on shares of Neurocrine Biosciences in a research report on Thursday, November 2nd. BMO Capital Markets reiterated an outperform rating and set a $84.00 price target on shares of Neurocrine Biosciences in a research report on Thursday, October 5th. Finally, ValuEngine upgraded Neurocrine Biosciences from a sell rating to a hold rating in a research report on Friday, September 1st. One analyst has rated the stock with a hold rating and eighteen have issued a buy rating to the company’s stock. Neurocrine Biosciences currently has an average rating of Buy and an average target price of $78.88.

Neurocrine Biosciences (NASDAQ NBIX) opened at $70.49 on Tuesday. The company has a quick ratio of 14.37, a current ratio of 14.38 and a debt-to-equity ratio of 1.05. Neurocrine Biosciences has a 1 year low of $37.35 and a 1 year high of $75.98.

Neurocrine Biosciences (NASDAQ:NBIX) last issued its quarterly earnings results on Wednesday, November 1st. The company reported ($0.13) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.49) by $0.36. The business had revenue of $60.77 million for the quarter, compared to analysts’ expectations of $29.38 million. During the same quarter in the prior year, the company posted ($0.43) EPS. research analysts anticipate that Neurocrine Biosciences will post -1.74 earnings per share for the current year.

In other news, insider Christopher Flint Obrien sold 6,925 shares of the firm’s stock in a transaction that occurred on Monday, October 2nd. The stock was sold at an average price of $61.04, for a total value of $422,702.00. Following the transaction, the insider now owns 55,898 shares in the company, valued at $3,412,013.92. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Darin Lippoldt sold 6,279 shares of the firm’s stock in a transaction that occurred on Monday, December 4th. The shares were sold at an average price of $75.04, for a total value of $471,176.16. Following the completion of the transaction, the insider now owns 19,436 shares in the company, valued at approximately $1,458,477.44. The disclosure for this sale can be found here. In the last 90 days, insiders sold 90,877 shares of company stock worth $6,568,617. Company insiders own 4.80% of the company’s stock.

Institutional investors have recently made changes to their positions in the stock. The Manufacturers Life Insurance Company lifted its position in Neurocrine Biosciences by 7.8% during the second quarter. The Manufacturers Life Insurance Company now owns 2,665 shares of the company’s stock worth $123,000 after buying an additional 193 shares in the last quarter. Comerica Bank purchased a new position in Neurocrine Biosciences during the third quarter worth approximately $210,000. Trexquant Investment LP purchased a new position in Neurocrine Biosciences during the third quarter worth approximately $246,000. World Asset Management Inc purchased a new position in Neurocrine Biosciences during the third quarter worth approximately $246,000. Finally, Stifel Financial Corp purchased a new position in Neurocrine Biosciences during the third quarter worth approximately $246,000.

TRADEMARK VIOLATION NOTICE: “Neurocrine Biosciences (NBIX) Given a $85.00 Price Target at Oppenheimer” was first published by Community Financial News and is the property of of Community Financial News. If you are viewing this piece of content on another website, it was illegally stolen and reposted in violation of international copyright & trademark laws. The legal version of this piece of content can be accessed at https://www.com-unik.info/2017/12/16/neurocrine-biosciences-nbix-given-a-85-00-price-target-at-oppenheimer.html.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences, Inc is engaged in discovering and developing pharmaceuticals, in diseases with unmet medical needs, through its research and development (R&D) platform, focused on neurological and endocrine based diseases and disorders. Its three lead late-stage clinical programs are elagolix, which is a gonadotropin-releasing hormone (GnRH) antagonist for endometriosis and uterine fibroids; INGREZZA (valbenazine), which is a vesicular monoamine transporter 2 (VMAT2) inhibitor, for the treatment of movement disorders, and opicapone, which is a selective catechol-O-methyltransferase inhibitor that is an adjunct therapy to preparations of levodopa/Dihydroxyphenylalanine (DOPA) decarboxylase inhibitors for adult patients with Parkinson’s disease.

Analyst Recommendations for Neurocrine Biosciences (NASDAQ:NBIX)

Receive News & Ratings for Neurocrine Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit